Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 298

1.

A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia.

Cohen JA, Rossi FM, Zucchetto A, Bomben R, Terzi-di-Bergamo L, Rabe KG, Degan M, Steffan A, Polesel J, Santinelli E, Innocenti I, Cutrona G, D' Arena G, Pozzato G, Zaja F, Chiarenza A, Rossi D, Di Raimondo F, Laurenti L, Gentile M, Morabito F, Neri A, Ferrarini M, Fegan CD, Pepper CJ, Del Poeta G, Parikh SA, Kay NE, Gattei V.

Haematologica. 2019 Oct 3. pii: haematol.2019.228171. doi: 10.3324/haematol.2019.228171. [Epub ahead of print]

2.

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.

Ferrero S, Rossi D, Rinaldi A, Bruscaggin A, Spina V, Eskelund CW, Evangelista A, Moia R, Kwee I, Dahl C, Di Rocco A, Stefoni V, Diop F, Favini C, Ghione P, Mahmoud AM, Schipani M, Kolstad A, Barbero D, Novero D, Paulli M, Zamò A, Jerkeman M, Gomez da Silva M, Santoro A, Molinari A, Ferreri A, Grønbæk K, Piccin A, Cortelazzo S, Bertoni F, Ladetto M, Gaidano G.

Haematologica. 2019 Sep 19. pii: haematol.2018.214056. doi: 10.3324/haematol.2018.214056. [Epub ahead of print]

3.

Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.

Schwotzer R, Manz MG, Pederiva S, Waibel C, Caspar C, Lerch E, Flammer AJ, Brouwers S, Seeger H, Heimgartner R, Fehr T, Rossi D, Bianchi E, Stüssi G, Ghilardi G, Gerber B.

Hematol Oncol. 2019 Sep 5. doi: 10.1002/hon.2677. [Epub ahead of print]

PMID:
31486522
4.

Oprozomib in patients with newly diagnosed multiple myeloma.

Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, Fujii H, Jakubowiak AJ, Rossi D, Sonneveld P.

Blood Cancer J. 2019 Aug 16;9(9):66. doi: 10.1038/s41408-019-0232-6. No abstract available.

5.

Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome.

Vannata B, Conconi A, Winkler J, Cascione L, Margiotta Casaluci G, Nassi L, Moia R, Pirosa MC, Moccia AA, Stathis A, Rossi D, Gaidano G, Zucca E.

Br J Haematol. 2019 Nov;187(4):478-487. doi: 10.1111/bjh.16106. Epub 2019 Aug 5.

PMID:
31385291
6.

Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.

Diop F, Moia R, Favini C, Spaccarotella E, De Paoli L, Bruscaggin A, Spina V, Terzi-di-Bergamo L, Arruga F, Tarantelli C, Deambrogi C, Rasi S, Adhinaveni R, Patriarca A, Favini S, Sagiraju S, Jabangwe C, Kodipad AA, Peroni D, Mauro FR, Del Giudice I, Forconi F, Cortelezzi A, Zaja F, Bomben R, Rossi FM, Visco C, Chiarenza A, Rigolin GM, Marasca R, Coscia M, Perbellini O, Tedeschi A, Laurenti L, Motta M, Donaldson D, Weir P, Mills K, Thornton P, Lawless S, Bertoni F, Del Poeta G, Cuneo A, Follenzi A, Gattei V, Boldorini RL, Catherwood M, Deaglio S, Foá R, Gaidano G, Rossi D.

Haematologica. 2019 Aug 1. pii: haematol.2019.219550. doi: 10.3324/haematol.2019.219550. [Epub ahead of print]

7.

Quest of biomarkers for venetoclax-treated CLL.

Rossi D.

Blood. 2019 Jul 11;134(2):97-98. doi: 10.1182/blood.2019001189. No abstract available.

PMID:
31296538
8.

BioWolf: A Sub-10-mW 8-Channel Advanced Brain-Computer Interface Platform With a Nine-Core Processor and BLE Connectivity.

Kartsch V, Tagliavini G, Guermandi M, Benatti S, Rossi D, Benini L.

IEEE Trans Biomed Circuits Syst. 2019 Oct;13(5):893-906. doi: 10.1109/TBCAS.2019.2927551. Epub 2019 Jul 9.

PMID:
31295119
9.

HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.

Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R, Massaia M, Boccadoro M, Coscia M.

Haematologica. 2019 Jul 9. pii: haematol.2019.217430. doi: 10.3324/haematol.2019.217430. [Epub ahead of print]

10.

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.

Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, Newman AM, Dührsen U, Hüttmann A, Casasnovas O, Westin JR, Ritgen M, Böttcher S, Langerak AW, Roschewski M, Wilson WH, Gaidano G, Rossi D, Bahlo J, Hallek M, Tibshirani R, Diehn M, Alizadeh AA.

Cell. 2019 Jul 25;178(3):699-713.e19. doi: 10.1016/j.cell.2019.06.011. Epub 2019 Jul 4.

PMID:
31280963
11.

Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14).

Ghilardi G, Stussi G, Mazzucchelli L, Röcken C, Rossi D, Gerber B.

Amyloid. 2019 Sep;26(3):173-174. doi: 10.1080/13506129.2019.1615428. Epub 2019 Jun 22. No abstract available.

PMID:
31232114
12.

The future of cell-free DNA testing to guide therapeutic decisions in B-cell lymphomas.

Condoluci A, Rossi D.

Curr Opin Hematol. 2019 Jul;26(4):281-287. doi: 10.1097/MOH.0000000000000516.

PMID:
31082825
13.

Online Learning and Classification of EMG-Based Gestures on a Parallel Ultra-Low Power Platform Using Hyperdimensional Computing.

Benatti S, Montagna F, Kartsch V, Rahimi A, Rossi D, Benini L.

IEEE Trans Biomed Circuits Syst. 2019 Jun;13(3):516-528. doi: 10.1109/TBCAS.2019.2914476. Epub 2019 May 2.

PMID:
31056519
14.

Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses.

Cascione L, Rinaldi A, Bruscaggin A, Tarantelli C, Arribas AJ, Kwee I, Pecciarini L, Mensah AA, Spina V, Chung EYL, di Bergamo LT, Dirnhofer S, Tzankov A, Miranda RN, Young KH, Traverse-Glehen A, Gaidano G, Swerdlow SH, Gascoyne R, Rabadan R, Ponzoni M, Bhagat G, Rossi D, Zucca E, Bertoni F.

Haematologica. 2019 Dec;104(12):e558-e561. doi: 10.3324/haematol.2018.214957. Epub 2019 Apr 24. No abstract available.

15.

Liquid biopsy in lymphoma.

Rossi D, Spina V, Bruscaggin A, Gaidano G.

Haematologica. 2019 Apr;104(4):648-652. doi: 10.3324/haematol.2018.206177. Epub 2019 Mar 7. No abstract available.

16.

FBXW7 is a biologically validated cancer driver gene for CLL.

Rossi D.

Blood. 2019 Feb 21;133(8):774-776. doi: 10.1182/blood-2018-12-891507. No abstract available.

PMID:
30792223
17.

Reply to J. Wang et al.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas O, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA.

J Clin Oncol. 2019 Mar 20;37(9):755-757. doi: 10.1200/JCO.18.01907. Epub 2019 Feb 12. No abstract available.

PMID:
30753108
18.

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.

Hicks SW, Tarantelli C, Wilhem A, Gaudio E, Li M, Arribas AJ, Spriano F, Bordone R, Cascione L, Lai KC, Qiu Q, Taborelli M, Rossi D, Stussi G, Zucca E, Stathis A, Sloss CM, Bertoni F.

Haematologica. 2019 Aug;104(8):1633-1639. doi: 10.3324/haematol.2018.211011. Epub 2019 Feb 7.

19.

Genome-wide promoter methylation of hairy cell leukemia.

Arribas AJ, Rinaldi A, Chiodin G, Kwee I, Mensah AA, Cascione L, Rossi D, Kanduri M, Rosenquist R, Zucca E, Johnson PW, Gaidano G, Oakes CC, Bertoni F, Forconi F.

Blood Adv. 2019 Feb 12;3(3):384-396. doi: 10.1182/bloodadvances.2018024059.

20.

Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment.

Condoluci A, Rossi D.

Expert Rev Hematol. 2019 Feb;12(2):89-98. doi: 10.1080/17474086.2019.1575130. Epub 2019 Feb 6.

PMID:
30686074

Supplemental Content

Loading ...
Support Center